## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SERIAL NOS.: See attached Schedule A ASSIGNEE: TargeGen, Inc.

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST REVOCATION OF PRIOR POWERS AND NEW POWER OF ATTORNEY

Sir:

As an authorized representative of the assignee of record of the entire right, title, and interest in the patent applications identified in the attached Schedule A, I hereby revoke all powers of attorney previously given and hereby appoint the registered patent practitioners associated with Customer Number 051414 to prosecute and transact all business in the U.S. Patent and Trademark Office connected therewith.

Please direct all correspondence for the above-identified patent applications to the address associated with the above Customer Number.

The assignee of record of the entire right, title, and interest in the above-identified patent applications is **TargeGen**, **Inc.** by virtue of the chain of title from the inventors of the above-identified patent applications to the current assignee.

Respectfully submitted,

Dated: September 6, 2007

Peter G. Ulrich, President and CEO

TargeGen, Inc.

9380 Judicial Drive

San Diego, California 92121 United States of America

## Schedule A

Application	Filing	Title	Attorney Docket	Reel and
No./Patent	Date		No./Former	Frame
No.			Attorney Docket No.	Number
7,208,493	10/02/03	Vasculostatic Agents and Methods	TRG-	014666/0766
		of Use Thereof	111/TARG-	
			1110-3	0444440
11/653,190	01/11/07	Vasculostatic Agents and Methods	TRG-	014666/0766
		of Use Thereof	111C1/TARG-	
	04/12/05	77 1 1 1 1 1 1 1 1 1	1110-5 TRG-	016023/0024
11/105,845	04/13/05	Vasculostatic Agents and Methods		016023/0024
	1	of Use Thereof	111CP/TARG- 1110-4	
60/415.001	10/02/02	SRC Inhibitors and Methods for	TRG-	103586/0793
60/415,981	10/03/02	Use Thereof	111P1/TARG-	103380/0793
		Use Thereof	1110	
60/440,234	01/14/03	SRC Inhibitors and Methods for	TRG-	013776/0484
60/440,234	01/14/03	Use Thereof	111P2/TARG-	013770/0464
		Ose Thereor	1110-1	
60/479,295	06/17/03	Vascular Permeability Inhibitors	TRG-	014458/0427
00/4/9,293	00/1//03	and Methods for Use Thereof	111P3/TARG-	011130/012/
		and Methods for OSC Thereof	1110-2	
11/102,405	04/07/05	Benzotriazine Inhibitors of	TRG-	016424/0283
11,102,103	0 11011100	Kinases	116/TARG-	
			1160-2	
60/561,237	04/08/04	Benzotriazine Inhibitors of	TRG-	016467/0841
		Kinases	116P1/TARG-	
			1160	
60/643,439	01/12/05	Benzotriazine Inhibitors of	TRG-	016467-0864
		Kinases	116P2/TARG-	1
			1160-1	
11/212,064	08/24/05	Heterocyclic Compounds and	TRG-	019411/0368
		Methods of Use	121/TARG-	
			1210-2	
60/604,298	08/25/04	Heterocyclic Compounds and	TRG-	01941/0301
		Methods of Use	121P1/TARG-	
			1210	
60/696,168	07/01/05	Heterocyclic Compounds and	TRG-	019411/0334
		Methods of Use	121P2/TARG-	
			1210-1	010010/0515
11/377,234	03/15/06	Pyrimidine Inhibitors of Kinases	TRG-123-	018049/0517
			1/TARG-1230-1	

Application	Filing	Title	Attorney Docket	Reel and
No./Patent	Date	The	No./Former	Frame
No.	Butte		Attorney Docket	Number
110.			No.	rvamoer
11/449,219	06/07/06	Methods and Compositions for the	TRG-	018610/0877
,2,	00,01,00	Treatment of Ocular Disorders	124/TARG-	010010/00//
		Transfer of Senial Biboraers	1240-3	
60/689,111	06/08/05	Methods and Compositions for the	TRG-	016467/0847
,		Delivery of Lipophilic Drugs	124P1/TARG-	
		<b>, ,</b> - <b>,</b>	1240	
60/763,537	01/30/06	Methods and Compositions for the	TRG-	018610/0877
		Delivery of Lipophilic Drugs	124P2/TARG-	
			1240-1	
11/588,638	10/26/06	Bi-Aryl Meta-Pyrimidine	TRG-	018791/0911
		Inhibitors of Kinases	125/TARG-	!
			1250-2	
11/796,717	04/26/07	Bi-Aryl Meta-Pyrimidine	TRG-	019600/0122
		Inhibitors of Kinases	125CP/TARG-	
			1250-3	
60/732,629	11/01/05	Bi-Aryl Meta-Pyrimidine	TRG-	018916/0540
		Inhibitors of Kinases	125P1/TARG-	
			1250	
60/838,003	08/15/06	Bi-Aryl Meta-Pyrimidine	TRG-	018782/0239
		Inhibitors of Kinases	125P2/TARG-	
			1250-1	
11/591,076	10/31/06	Inhibitors Targeting Resistant	TRG-	018964/0673
		Kinase	126A/TARG-	
			1260A-1	
11/591,252	10/31/06	Thiazole Inhibitors Targeting	TRG-	018964/0732
		Resistant Kinase Mutations	126B/TARG-	
			1260-2	
11/772,572	07/02/07	2-Amino-5-Substituted Pyrimidine	TRG-	019774/0567
		Inhibitors	127/TARG-	[
			1270-1	
11/789,832	04/25/07	Kinase Inhibitors and Methods of	TRG-	019600/0230
		Use Thereof	128/TARG-	
	<u> </u>	L	1280-1	